PET Imaging with [⁶⁸Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [¹⁸F]Fluorodeoxyglucose and [¹⁸F]Fluoroethylcholine

Title:PET Imaging with [⁶⁸Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [¹⁸F]Fluorodeoxyglucose and [¹⁸F]Fluoroethylcholine

Volume: 14 Issue: 4

Author(s): Ina Israel, Dominik Richter, Jochen Stritzker, Michaela van Ooschot, Ulrike Donat, Andreas K. Buck and Samuel Samnick

Affiliation:

Keywords: Angiogenesis, α_vβ₃ integrin, [⁶⁸Ga]NOTA-RGD, PET imaging, prostate cancer.

Abstract: The α_vβ₃ integrin is highly expressed in prostate cancer (PCa), in which it is a key player in tumour invasion, angiogenesis and metastasis formation. Therefore, α_vβ₃ integrin is considered a very promising target for molecular imaging of PCa. This study tested the potential of the novel α_vβ₃ integrin affine agent [⁶⁸Ga]NOTA-RGD in comparison with the established [¹⁸F]fluoroethylcholine (FEC) and [¹⁸F]fluorodeoxyglucose (FDG) for assessing PCa using positron emission tomography (PET). [⁶⁸Ga]NOTA-RGD showed a lower uptake in PC-3 and DU-145 cells compared with FEC and FDG. µPET imaging studies showed a good delineation of the PCa xenografts in mice. The means tumor-to-muscleand tumor-to-bone-ratio amounted 5.1 ± 1.4 and 5.2 ± 1.2 for [⁶⁸Ga]NOTA-RGD compared with 2.6 ± 0.9 and 2.9 ± 1.6 for FDG, and 2.4 ± 0.7 and 0.8 ± 0.2 for FEC, respectively. The uptake of [⁶⁸Ga]NOTA-RGD into tumor was fully inhibited by c(RGDfV), known to bind specifically to α_vβ₃ integrin, confirming the specificity of the tumor uptake in vivo. These results suggest that [⁶⁸Ga]NOTA-RGD is a promising candidate for PET imaging of α_vβ₃ integrin expression in PCa and warrant further in vivo validations to ascertain its potential as an imaging agent for clinical use. The simple and fast preparation of [⁶⁸Ga]NOTA-RGD may greatly facilitate its translation to a clinical setting.

Cite this article as:

Israel Ina, Richter Dominik, Stritzker Jochen, Ooschot van Michaela, Donat Ulrike, Buck K. Andreas and Samnick Samuel, PET Imaging with [⁶⁸Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [¹⁸F]Fluorodeoxyglucose and [¹⁸F]Fluoroethylcholine, Current Cancer Drug Targets 2014; 14 (4) . https://dx.doi.org/10.2174/1568009614666140403123452